id: peth_based_risk_stratification_to_withdrawal_medication_initiation
name: PEth-Based Risk Stratification for Withdrawal â†’ Appropriate Withdrawal Medication
  Initiation
from_node:
  node_id: peth_based_risk_stratification
  node_name: PEth-Based Risk Stratification for Withdrawal
to_node:
  node_id: withdrawal_medication_initiation
  node_name: Appropriate Withdrawal Medication Initiation
direction: positive
category: healthcare_access
mechanism_pathway:
- 'Step 1: PEth biomarker testing on admission provides objective measure of alcohol
  exposure and withdrawal risk'
- 'Step 2: Higher PEth levels identify patients who will likely reach AWS score of
  6 or more (medication threshold)'
- 'Step 3: Early risk stratification enables proactive medication planning rather
  than reactive treatment'
- 'Step 4: Appropriate early medication initiation prevents progression to severe
  withdrawal complications including seizures and delirium tremens'
evidence:
  quality_rating: C
  n_studies: 1
  primary_citation: Lan Novak et al. 2023. "Alcohol Biomarker Phosphatidylethanol
    as a Predictor of the Severity of Alcohol Withdrawal Syndrome.." *Alcohol and
    Alcoholism*. https://doi.org/10.1093/alcalc/agac071
last_updated: '2025-12-02'
version: '1.0'
llm_metadata:
  extracted_by: claude-sonnet-4-5-20250929
  extraction_date: '2025-12-02T18:12:06.700457'
  batch_id: msgbatch_01AKnPJgzm7Fk9qubgAz9GaD
moderators:
- name: healthcare_setting_resources
  direction: strengthens
  strength: strong
  description: Settings with laboratory capacity for PEth testing and trained medical
    staff for AWS assessment can implement this risk stratification approach
- name: insurance_coverage
  direction: strengthens
  strength: moderate
  description: Coverage for biomarker testing determines which patients can benefit
    from PEth-based risk stratification
